Type I diabetes is an exhausting full-time job. Having it means living a life full of constant care and maintenance. You’re always checking in on your blood sugar to make sure it isn’t too high or is it too low, extremes that could be easily reached with the most minor indulgence or tiniest bout of laziness.
A new treatment, as detailed in the New York Times, might change everything we know about managing type I diabetes.
Zimislecel is an experimental stem cell-based therapy that recently dropped a bomb on the diabetes world. Developed by the Boston-based Vertex Pharmaceuticals, it’s a one-time infusion that has turned 10 of 12 trial patients suffering from severe type I diabetes into people who no longer need insulin, and in less than a year.